ReviewFrontiers in oncology2026
UTROSCT: a case report and scoping review of ultrasound features, with exploratory serum proteomic findings.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: UTROSCT is a rare uterine neoplasm with nonspecific imaging features. The aim of this study was to evaluate how UTROSCT is described on pelvic and transvaginal ultrasound in the published case-report literature and to report the clinicopathologic, immunophenotypic, and exploratory serum proteomic features of a new UTROSCT case. Case presentation: Transvaginal ultrasound revealed an intracavitary uterine lesion in a 72-year-old asymptomatic postmenopausal woman. Histopathology and immunohistochemistry on biopsy and hysterectomy specimens supported the diagnosis of group II UTROSCT with no myometrial invasion and no lymph node involvement. Exploratory serum proteomic analysis, performed as a hypothesis-generating approach, suggested enrichment of extracellular matrix-related proteins compared with a healthy control and an endometrial stromal sarcoma control. Materials and methods scoping review: We searched MEDLINE (PubMed), Scopus, and Google Scholar from January 2004 to December 2025 to identify English-language case reports of histologically confirmed UTROSCT that included at least one pelvic/transvaginal ultrasonographic assessment. Records were screened independently by two reviewers. The review was conducted and reported according to PRISMA ScR. Data were charted using a predefined form capturing age and ultrasound presentation categories (e.g., fibroid-like, polyp-like, pelvic mass/unspecified). Reporting quality was appraised using the JBI Critical Appraisal Checklist for Case Reports; appraisal results were not used for exclusion. Results scoping review: Out of 359 case reports identified, only 99 were included in the evidence mapping. The mean age of the examined population is 49.2 years. The results of our review showed that UTROSCT presents as a fibroid in the majority of cases (46.5%). Discussion and conclusions: Diagnosis of UTROSCTs could be challenging because it is a rare condition. The ultrasound appearance is heterogeneous and often not accurately reported in literature. Our review shows that UTROSCT most frequently mimics leiomyoma at ultrasound. In our case report, exploratory serum proteomics may generate hypotheses for future translational research but requires tissue-level validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.